Search

Your search keyword '"Zhang, Tian-Song"' showing total 12 results
Start Over Author "Zhang, Tian-Song" Search Limiters Full Text
12 results on '"Zhang, Tian-Song"'

2. In-depth mining of clinical data: the construction of clinical prediction model with R

Author

Zhou, Zhi-Rui, primary, Wang, Wei-Wei, additional, Li, Yan, additional, Jin, Kai-Rui, additional, Wang, Xuan-Yi, additional, Wang, Zi-Wei, additional, Chen, Yi-Shan, additional, Wang, Shao-Jia, additional, Hu, Jing, additional, Zhang, Hui-Na, additional, Huang, Po, additional, Zhao, Guo-Zhen, additional, Chen, Xing-Xing, additional, Li, Bo, additional, and Zhang, Tian-Song, additional

Published
2019
Full Text
View/download PDF

5. The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease

Author

Chen, Yu Jie, Chen, Ling Xiao, Han, Mei Xiang, Zhang, Tian Song, Zhou, Zhi Rui, and Zhong, Dian Sheng

Subjects
Lung Neoplasms, Prognosis, Disease-Free Survival, Survival Rate, Treatment Outcome, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Disease Progression, Humans, Lung Diseases, Interstitial, Systematic Review and Meta-Analysis, Research Article
Abstract

Supplemental Digital Content is available in the text, Chemotherapy plays a critical and venturous role against the co-morbidity of nonsmall cell lung cancer and interstitial lung disease (NSCLC–ILD). We performed a Bayesian meta-analysis and systematic review to evaluate the safety and efficacy of the chemotherapy in NSCLC–ILD patients. EMBASE, PubMed, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov (up to January 2015). We included all study designs except case reports, all studies with NSCLC–ILD patients and all the possible chemotherapy regimens. Quality was assessed by a components approach. We derived summary estimates using Bayesian method through WinBUGS (version 1.4.3, MRC Biostatistics Unit, Cambridge, UK). Seven studies involving 251 patients with NSCLC–ILD were included in the meta-analysis. The treatment response (complete remission, 0; [partial remission, 39.1%; 95% credible interval [CrI], 32.6–45.7]; [stable disease, 36%; 95% CrI, 29.6–42.2]; [PD, 15.4%; 95% CrI, 11.3–19.8]; [nonevaluable, 6.4%; 95% CrI, 2.7–10.1]; [overall response rate, 41.3%; 95% CrI, 35.3–47.4]; [disease control rate, 77.7%; 95% CrI, 72.2–82.7]) were comparable to that of patients with NSCLC alone; the survival outcomes (median overall survival, median progression-free survival, and 1-year survival rate) were slightly worse, especially the lower 1-year survival rate. Platinum-based doublets as first-line chemotherapy may be related to higher incidence of acute exacerbation-ILD in first line chemotherapy (AE, 8.47%; 95% CrI, 5.04–12.6). The data selection bias and small patient number make the meta-analysis of treatment response and conclusions generated from these data inaccurate. The present meta-analysis suggests that chemotherapy might be an effective therapy for patients with NSCLC–ILD, but it might be associated with higher incidence of acute exacerbation.

Published
2015

12. MK-801 attenuates lesion expansion following acute brain injury in rats: a meta-analysis.

Author

Yi NX, Zhou LY, Wang XY, Song YJ, Han HH, Zhang TS, Wang YJ, Shi Q, Xu H, Liang QQ, and Zhang T

Abstract

Objective: To evaluate the efficacy and safety of MK-801 and its effect on lesion volume in rat models of acute brain injury., Data Sources: Key terms were "stroke", "brain diseases", "brain injuries", "brain hemorrhage, traumatic", "acute brain injury", "dizocilpine maleate", "dizocilpine", "MK-801", "MK801", "rat", "rats", "rattus" and "murine". PubMed, Cochrane library, EMBASE, the China National Knowledge Infrastructure, WanFang database, the VIP Journal Integration Platform (VJIP) and SinoMed databases were searched from their inception dates to March 2018., Data Selection: Studies were selected if they reported the effects of MK-801 in experimental acute brain injury. Two investigators independently conducted literature screening, data extraction, and methodological quality assessments., Outcome Measures: The primary outcomes included lesion volume and brain edema. The secondary outcomes included behavioral assessments with the Bederson neurological grading system and the water maze test 24 hours after brain injury., Results: A total of 52 studies with 2530 samples were included in the systematic review. Seventeen of these studies had a high methodological quality. Overall, the lesion volume (34 studies, n = 966, MD = -58.31, 95% CI: -66.55 to -50.07; P < 0.00001) and degree of cerebral edema (5 studies, n = 75, MD = -1.21, 95% CI: -1.50 to -0.91; P < 0.00001) were significantly decreased in the MK-801 group compared with the control group. MK-801 improved spatial cognition assessed with the water maze test (2 studies, n = 60, MD = -10.88, 95% CI: -20.75 to -1.00; P = 0.03) and neurological function 24 hours after brain injury (11 studies, n = 335, MD = -1.04, 95% CI: -1.47 to -0.60; P < 0.00001). Subgroup analysis suggested an association of reduction in lesion volume with various injury models (34 studies, n = 966, MD = -58.31, 95% CI: -66.55 to -50.07; P = 0.004). Further network analysis showed that 0-1 mg/kg MK-801 may be the optimal dose for treatment in the middle cerebral artery occlusion animal model., Conclusion: MK-801 effectively reduces brain lesion volume and the degree of cerebral edema in rat models of experimental acute brain injury, providing a good neuroprotective effect. Additionally, MK-801 has a good safety profile, and its mechanism of action is well known. Thus, MK-801 may be suitable for future clinical trials and applications., Competing Interests: None

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results